


1645



Please type a plus sign (+) inside this box → ☐

PTO/SB/21 (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

Application Number	09/807,506
Filing Date	October 12, 1999
First Named Inventor	Blumenfeld, et al.
Group Art Unit	1645
Examiner Name	Unassigned
Attorney Docket Number	50.US3.PCT

RECEIVED

MAY 16 2002

TECH CENTER 1600/2900

Total Number of Pages in This Submission

ENCLOSURES (check all that apply)

- ☐ Fee Transmittal Form
- ☐ Fee Attached
- ☒ Amendment / Reply
- ☐ After Final
- ☐ Affidavits/declaration(s)
- ☐ Extension of Time Request
- ☐ Express Abandonment Request
- ☒ Information Disclosure Statement
- ☐ Certified Copy of Priority Document(s)
- ☐ Response to Missing Parts/Incomplete Application
- ☐ Response to Missing Parts under 37 CFR 1.52 or 1.53

- ☐ Assignment Papers (for an Application)
- ☐ Drawing(s)
- ☐ Licensing-related Papers
- ☐ Petition
- ☐ Petition to Convert to a Provisional Application
- ☐ Power of Attorney, Revocation Change of Correspondence Address
- ☐ Terminal Disclaimer
- ☐ Request for Refund
- ☐ CD, Number of CD(s) _____

- ☐ After Allowance Communication to Group
- ☐ Appeal Communication to Board of Appeals and Interferences
- ☐ Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
- ☐ Proprietary Information
- ☐ Status Letter
- ☒ Other Enclosure(s) (please identify below):
Copies of 40 prior art references;
Return Receipt Postcard

Remarks

This 371 application was filed April 13, 2001 and it's date of entry was August 6, 2001.

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm
or
Individual name

Deno Dialynas, Ph.D.

Reg. No. 50,711

Signature

Deno P. Dialynas

Date

May 9, 2002

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231 on this date: _____

Typed or printed name

Deno P. Dialynas

Signature

Deno P. Dialynas

Date

May 9, 2002

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

RECEIVED

MAY 16 2002

TECH CENTER 1600/2900



Docket/Matter No. 50.US3.PCT

#7
188

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

MAY 16 2002

TECH CENTER 1600/2900

In re the Application of:

Applicant : Marta BLUMENFELD, et al.

Appl. No. : 09/807,506

Filed : April 13, 2001

Date of Entry : August 6, 2001

Priority Intern'l Appl. No. : PCT/IB99/01730

Filed : October 12, 1999

Title : GENES, PROTEINS AND BIALLELIC MARKERS
RELATED TO CENTRAL NERVOUS SYSTEM
DISEASE

Grp./A.U. : 1645

Examiner : Unassigned

Honorable Commissioner of Patents
Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT

Sir:

Applicant submits the references listed on the attached forms PTO/SB/08A and 08B, copies of which are enclosed. This statement is being filed before the receipt of a first Office Action on the merits. Nine of the forty references were cited in an International Search Report (copy enclosed), and I, the undersigned, hereby certify that each of those items was cited in a communication from a foreign patent office in a counterpart foreign application.

The U.S. Patent No. 6,291,182, issued September 18, 2001 is owned by the Assignee of the above-identified application. In addition, foreign patent Publication No. WO 01/40493, published on June 7, 2001 was filed by the Assignee of the above-identified application.

Appln. No. 09/807,506

Filed: April 12, 2001 (Date of Entry: August 6, 2001)


Page 2

The Commissioner is hereby authorized to charge any fees in connection with this document to our Deposit Account No.: 50-1181

Respectfully submitted,

GENSET CORPORATION

Date: May 9, 2002

By: 
Deno Dialynas, Ph.D.
Registration No. 50,711

10665 Sorrento Valley Road
San Diego, CA 92121-1609


Telephone: (858) 597-2600

Facsimile: (858) 597-2601


e-mail: deno.dialynas@genxy.com

Certificate of Mailing under 37 CFR 1.10

Date of Deposit: May 9, 2002
I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail, on the Date of Deposit shown above, postage prepaid and in an envelope addressed to the Commissioner of Patents and Trademarks, Washington, D.C. 20231.


Signature

Deno P. Dialynas
Typed or Printed Name of Person Signing Certificate



Under the Paper
control number

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Required to respond to a collection of information unless it contains a valid OMB

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet	1	of	5
-------	---	----	---

Complete if Known

Application Number	09/807,506
Filing Date	Int.Apl.:10/10/1999 (08/06/2001)
First Named Inventor	Blumenfeld, et al.
Art Unit	1645
Examiner Name	Unassigned
Attorney Docket Number	50.US3.PCT

U.S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

[illegible]


Examiner
Signature

Date
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



PTO/SB/08B (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 3 of 5

Complete if Known

Application Number	09/807,506
Filing Date	Int.Apl.:10/10/1999 (08/06/2001)
First Named Inventor	Blumenfeld, et al.
Group Art Unit	1645
Examiner Name	Unassigned
Attorney Docket Number	50.US3.PCT

RECEIVED

MAY 15 2002
TECH CENTER 1600/2900

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	O	LIN, ET AL.; "Suggestive evidence for linkage of schizophrenia to markers on chromosome 13 in Caucasian but not Oriental populations"; Hum Genet (1997) 99:417-420; Springer-Verlag 1997	
	P	KELSOE, ET AL.; "A genome survey indicates a possible susceptibility locus for bipolar disorder on chromosome 22"; PNAS; January 16, 2001; Vol. 98, No. 2, pp. 585-590; www.pnas.org	
	Q	CIMATO, ET AL.; "Nerve growth factor-specific regulation of protein methylation during neuronal differentiation of PC12 Cells"; The Rockefeller University Press, 0021-9525/97/09/1089/15; The Journal of Cell Biology, Vol. 138, No. 5, September 8, 1997; pgs. 1089-1103; http://www.jcb.org	
	R	BASSETT; ET AL.; "Evidence for anticipation in schizophrenia"; Am. J. Hum. Genet. 54:864-870, 1994; The American Society of Human Genetics; 0002-9297/94/5405-0016	
	S	McINNIS, ET AL.; "Anticipation in bipolar affective disorder"; Am. J. Hum. Genet. 53:385-390, 1993; The American Society of Human Genetics; 0002-9297/93/5302-0010	
	T	ZONANA, ET AL.; "X-linked Hypohidrotic Ectodermal Dysplasia: localization within the region Xq11-21.1 by Linkage Analysis and Implications for Carrier Detection and Prenatal Diagnosis"; Am. J. Hum. Genet. 43:075-085, 1988; The American Society of Human Genetics; 0002-9297/99/4301-0011	
	U	Accession: AF087142; Zonana, et al.; "Isolation and characterization of a human X-linked gene mapping to the Xq13.1 region"; Unpublished	
	V	FIRESTEIN, ET AL.; "Cypin: a cytosolic regulator of PSD-95 postsynaptic targeting"; Neuron, Vol. 24, 659-672, Nov. 1999; Cell Press	
	W	DeSTROOPER, ET AL.; "Phosphorylation, subcellular localization, and membrane orientation of the Alzheimer's Disease-associated Presenilins"; Vol. 272, No. 6, February 27, 1997; pp. 3590-3598; The American Society for Biochemistry and Molecular Biology, Inc.	
	X	AOKI, ET AL.; "The novel protein-tyrosine phosphatase PTP20 is a positive regulator of PC12 Cell Neuronal Differentiation"; Vol. 271, No. 46, November 15, 1996, pp. 29422-29426; The American Society for Biochemistry and Molecular Biology, Inc.	
	Y	WASIAK, ET AL.; "The Ras/Rac Guanine Nucleotide Exchange Factor Mammalian Son-of sevenless Interacts with PACSIN 1/Syndapin I, a Regulator of Endocytosis and the Actin Cytoskeleton"; The Journal of Biological Chemistry; Vol.276, No. 28, July 13, pp. 26622-26628, 2001; The American Society for Biochemistry and Molecular Biology, Inc.	

Examiner
Signature

Date
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



PTO/SB/08B (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 4 of 5

Complete if Known

Application Number	09/807,506
Filing Date	Int. Appl.: 10/10/1999 (08/08/2001)
First Named Inventor	Blumenfeld, et al.
Group Art Unit	
Examiner Name	Unassigned
Attorney Docket Number	50.US3.PCT

RECEIVED
MAY 14 2002
TECH CENTER 1600/2900

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	Z	MARGOLIS, ET AL.; "cDNAs with long CAG trinucleotide repeats from human brain"; Hum Genet (1997) 100:111-122; Springer-Verlag 1997	
	AA	WEINBERGER, ET AL.; "Neurobiology of Schizophrenia and the Role of Atypical Antipsychotics - Prefrontal Neurons and the Genetics of Schizophrenia"; Biol Psychiatry 2001; 50:825-844; Society of Biological Psychiatry; 0006-3223/01; PII S0006-3223(01)01252-5	
	AB	BRANT, ET AL.; "Linkage Heterogeneity for the IBD1 Locus in Crohn's Disease Pedigrees by Disease Onset and Severity"; Gastroenterology 2000; 119:1483-1490; the American Gastroenterological Association 0016-5085/00	
	AC	WRIGHT, ET AL.; "Schizophrenia and HLA: a review"; Schizophrenia Research 47 (2001) 1-12; 0920-9964/01; Elsevier Science B.V.; PII: S0920-9964 (00) 00022-0	
	AD	KASHIMA, ET AL.; "Role of Unique Consecutive Glutamine Repeats in Active Murine Interleukin-2 Molecule"; J. Biochem, 102, 725-732 (1987)	
	AE	Accession: B75361; Adams, et al.; "Use of BAC End Sequences for Sequence-Ready Map Building"; Unpublished; XP-002135179	
	AF	Assession: AA989298; NCI-CGAP http://222.ncbi.nlm.nih.gov/ncicgap ; "National Cancer Institute, Cancer Genome Anatomy Project (CGAP) Tumor Gene Index"; Unpublished; XP-002135005	
	AG	Accession: L10374; Li, et al.; "Novel triplet repeat containing genes in human brain: cloning, expression, and length polymorphisms"; Genomics 16:572-579 (1993); XP-002134451	
	AH	WANG, ET AL.; "Large-scale identification, mapping, and genotyping of single-nucleotide polymorphisms in the human genome"; www.sciencemag.org; Science, Vol. 280, May 15, 1998; pp. 10771082; XP-002089398	
	AI	KRUGLYAK, L.; "The use of a genetic map of biallelic markers in linkage studies"; nature genetics, Vol. 17, September 1997, pp. 21-24; XP-002050647	
	AJ	NYLANDER, ET AL.; "Anticipation in Swedish families with bipolar affective disorder"; J. Med. Genet. 1994; 31:686-689	

Examiner
Signature

Date
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



RECEIVED

MAY 16 2002
CENTER 1600/2900

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
Sheet	5	of	5	Application Number	09/807.506
				Filing Date	Int.Ap.:10/10/1999 (05/04/2001)
				First Named Inventor	Blumenfeld, et al.
				Group Art Unit	1645
				Examiner Name	Unassigned
				Attorney Docket Number	50.US3.PCT

[illegible]

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.